Friday, 16 October 2026European Markets

ACOMO And B&S Group Have A High Dividend Yield And Return On Equity In The Food Distribution Industry.

Loading stream...

(VIANEWS) - ACOMO (ACOMO.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Food Distribution industry.

Financial Asset Price Forward Dividend Yield Return on Equity
ACOMO (ACOMO.AS) €22.40 5.73% 14.08%
B&S Group (BSGR.AS) €3.88 4.4% 16.82%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ACOMO (ACOMO.AS)

5.73% Forward Dividend Yield and 14.08% Return On Equity

Acomo N.V., together with its subsidiaries, engages in sourcing, trading, processing, packaging, and distributing conventional and organic food ingredients and solutions for the food and beverage industry worldwide. It operates through five segments: Spices and Nuts, Edible Seeds, Organic Ingredients, Tea, and Food Solutions. The Spices and Nuts segment provides tropical products, including pepper, nutmeg, desiccated coconut, shelled and unshelled nuts, dried fruits, dehydrated vegetables, herbs, rice crackers, and snack products. Its Edible Seeds segment trades, processes, and distributes edible seeds, such as poppy, sesame, pumpkin, and flax, as well as sunflower seeds comprising in-kernel and shelled for the snack and retail industries; birdseeds for wildlife; and edible seeds to bakery, spice, and confectionery industries. The Organic Ingredients segment provides a range of organic food products and ingredients in various categories, including cocoa, coffee, fruit and vegetables, edible seeds, nuts and dried fruits, oils, and premium juice products. Its Tea segment trades, processes, and distributes through warehouses and blending facilities; and monitors and analyzes market development, and shares insight to customers to meet traditional consumer preferences, which include novel appetites for specialty tea. The Food Solutions segment produces and supplies culinary and functional ingredients, plant-based solutions, wet and dry blends, and spice mixes to food companies; and provides product development, manufacturing, packaging, distribution, and inventory management services. The company was formerly known as Amsterdam Commodities N.V. and changed its name to Acomo N.V. in June 2022. Acomo N.V. was founded in 1908 and is based in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, ACOMO has a trailing twelve months EPS of €0.92.

PE Ratio

ACOMO has a trailing twelve months price to earnings ratio of 24.48. Meaning, the purchaser of the share is investing €24.48 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.08%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.1%, now sitting on 1.42B for the twelve trailing months.

More news about ACOMO.

2. B&S Group (BSGR.AS)

4.4% Forward Dividend Yield and 16.82% Return On Equity

B&S Group S.A. distributes consumer goods worldwide. The company operates through six segments: B&S Liquors, B&S Beauty, B&S Personal Care, B&S Food, B&S Health, and B&S Retail. The B&S Liquors segment distributes branded liquors to wholesalers, consumers, and e-commerce platforms. The B&S Beauty segment distributes and sells branded fragrances and cosmetics to wholesalers, consumers, and e-commerce platforms. The B&S Personal Care segment distributes and sells branded personal and home care products primarily to retailers. The B&S Food segment distributes a range of branded food and beverages products to duty-free, remote, retail, and maritime markets. The B&S Health segment distributes and sells branded medical products and equipment to maritime and remote markets, as well as pharmacies and travel clinics. The B&S Retail segment primarily operates retail stores that sells consumer electronics and multi-category assortments at international airports, regional airports, and other away from home locations. It also provides sourcing, warehousing, distribution, digital commerce, marketing, and brand development solutions. The company was incorporated in 2007 and is based in Betzdorf, Luxembourg.

Earnings Per Share

As for profitability, B&S Group has a trailing twelve months EPS of €0.258.

PE Ratio

B&S Group has a trailing twelve months price to earnings ratio of 15.04. Meaning, the purchaser of the share is investing €15.04 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.82%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 19, 2022, the estimated forward annual dividend rate is 0.18 and the estimated forward annual dividend yield is 4.4%.

Sales Growth

B&S Group's sales growth for the next quarter is negative 21.7%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, B&S Group's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for B&S Group is 40990 which is 67.84% below its average volume of 127473.

More news about B&S Group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com